Figure 4. PD-1 and CTLA-4 combination blockade decreases the percentage of Foxp3⁺CD4⁺ Tregs and increases the CD8/Treg and CD4/Treg ratio in TSC2-deficient tumors.

(A) Flow cytometry quantification of tumor-infiltrating Foxp3⁺CD4⁺ Tregs in TSC2-deficient 105K tumors (left) and TSC2-deficient TMKOC tumors (right) obtained 24 hours following the last treatment, as illustrated in Figure 2A. (B) Ratios of CD8⁺ T cells to Tregs and CD4⁺ T cells to Tregs within 105K tumors (left) and TSC2-deficient TMKOC tumors (right) are shown (n = 6–8 per group). Data are presented as mean ± SD. Statistical significance was determined by nonparametric 1-way ANOVA followed by Dunn’s multiple comparison test. *P < 0.05.